Literature DB >> 2073585

Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys.

J S Schneider1.   

Abstract

Chronic low-dose MPTP exposure was previously found to impair cognitive performance in monkeys. These monkeys developed deficits in performance of delayed response and delayed alternation tasks but maintained performance on visual pattern discrimination. This, along with other subtle behavioral changes, occurred in the absence of gross parkinsonian motor symptoms. The present study reports the results of neurochemical and neuropathological examination of the brains of these animals. Chronic low-dose MPTP exposure resulted in profound decreases in caudate dopamine (DA) levels and slightly less severe depletions in the putamen. Increases in striatal HVA/DA ratios suggest an increase in DA turnover in these areas. In contrast to striatal DA depletions, we found significant increases in striatal serotonin levels without an associated increase in serotonin turnover. At the cortical level, we found inconsistent changes in frontal cortical DA levels and variable decreases in norepinephrine levels. Since the most profound and consistent deficits were in the nigrostriatal dopamine system, we suggest that most of the behavioral consequences of chronic low-dose MPTP exposure stem from the striatal dopamine depletion. We also suggest that the maintenance of motor function in the presence of massive striatal DA depletions may be due to less impairment of putamen DA vs. caudate DA, by an increase in striatal DA turnover, a compensatory increase in serotonin availability, or a combination of these and possibly other as yet undetermined compensatory mechanisms. Furthermore, we propose the present model utilizing chronic low-dose exposure to MPTP as a model for the early, compensated form of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073585     DOI: 10.1016/0006-8993(90)90108-n

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism.

Authors:  J S Schneider; J P Tinker; E Decamp
Journal:  Behav Brain Res       Date:  2010-03-27       Impact factor: 3.332

2.  Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity.

Authors:  K K Gnanalingham; N A Milkowski; L A Smith; A J Hunter; P Jenner; C D Marsden
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 3.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

4.  MPTP-induced executive dysfunction is associated with altered prefrontal serotonergic function.

Authors:  Panchanan Maiti; Laura C Gregg; Michael P McDonald
Journal:  Behav Brain Res       Date:  2015-09-21       Impact factor: 3.332

5.  Modeling Parkinson's disease in primates: The MPTP model.

Authors:  Gregory Porras; Qin Li; Erwan Bezard
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

6.  Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs.

Authors:  T V Wade; J S Schneider
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

7.  Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  Lacey Pflibsen; Katherine A Stang; Michelle D Sconce; Vanessa B Wilson; Rebecca L Hood; Charles K Meshul; Suzanne H Mitchell
Journal:  J Neurosci Res       Date:  2015-08-31       Impact factor: 4.164

8.  Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease.

Authors:  R M Villalba; T Wichmann; Y Smith
Journal:  Brain Struct Funct       Date:  2013-03-19       Impact factor: 3.270

Review 9.  Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

Authors:  Wassilios Meissner; Caroline Prunier; Denis Guilloteau; Sylvie Chalon; Christian E Gross; Erwan Bezard
Journal:  Mol Neurobiol       Date:  2003-12       Impact factor: 5.590

10.  Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.

Authors:  E Decamp; J S Schneider
Journal:  Brain Res       Date:  2009-02-07       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.